Press Release with Hero - Video or Image

July 19, 2023

Overview

Publish date: Jul 19, 2023

Lorem ipsum dolor sit amet, consectetur adipiscing elit. 


Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec maximus dapibus semper. Sed ipsum ex, aliquam non lacinia et, porta ut turpis. In id tortor a nisl eleifend pellentesque quis id lacus. Nam dapibus augue diam, nec feugiat mauris malesuada nec. Quisque nec tempus metus, sit amet porttitor quam. Nam nibh enim, ultricies vitae molestie in, vulputate viverra purus. Cras eget efficitur urna. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Donec eu erat dolor. Nulla feugiat, massa sed mollis pulvinar, nibh dolor gravida tellus, eget scelerisque augue ipsum dapibus ex. Nulla facilisi. Aliquam urna lorem, imperdiet eget est in, accumsan lacinia quam.

Raise the bar for MedTech innovation to improve healthcare

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec maximus dapibus semper. Sed ipsum ex, aliquam non lacinia et, porta ut turpis. In id tortor a nisl eleifend pellentesque quis id lacus. Nam dapibus augue diam, nec feugiat mauris malesuada nec. Quisque nec tempus metus, sit amet porttitor quam. Nam nibh enim, ultricies vitae molestie in, vulputate viverra purus. Cras eget efficitur urna. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Donec eu erat dolor. Nulla feugiat, massa sed mollis pulvinar, nibh dolor gravida tellus, eget scelerisque augue ipsum dapibus ex. Nulla facilisi. Aliquam urna lorem, imperdiet eget est in, accumsan lacinia quam.

Lorem ipsum dolor sit amet

While driving local innovation, BD is also actively seeking strategic collaboration with local partners. 

Firstly, BD signed a framework agreement on pharmacy dispensing robots with Hangzhou Zetian Chunlai Technology Co., Ltd. Under the agreement, the two companies will work closely with each other for local innovation and local manufacturing in a local ecosystem, and to serve the construction of smart pharmacies and smart hospitals in China in a faster, better and more pertinent manner. Meanwhile, BD also signed an agreement with Yadu Holdings Group for strategic collaboration project on innovative urine drainage solution. Through this project, BD wants to bring its groundbreaking female external catheters to China faster, so that local patients can benefit from this global medtech product as early as possible, while providing a strong driver for the company’s sustainable growth in China.

Prior to the inauguration of the GCTIC, BD had already signed agreements with the first Chinese customers for its latest RhapsodyTM HT Xpress System, a higher-throughput platform for analyzing single cells. This epoch-making single-cell multiomics analysis platform is able to run million cell studies easily. BD was able to sell 6 units of this system to Chinese customers when they formally saw the product for the first time after its launch. 

In addition, after the opening of GCTIC, BD launched National Laboratory Competency Building and Quality Management Improvement Project, building specialized communication platform cooperated with national laboratory KOLs, College of American Pathologists, etc.

Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec maximus dapibus semper. Sed ipsum ex, aliquam non lacinia et, porta ut turpis. In id tortor a nisl eleifend pellentesque quis id lacus. Nam dapibus augue diam, nec feugiat mauris malesuada nec.

Quisque nec tempus metus, sit amet porttitor quam. Nam nibh enim, ultricies vitae molestie in, vulputate viverra purus. Cras eget efficitur urna. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Donec eu erat dolor. Nulla feugiat, massa sed mollis pulvinar, nibh dolor gravida tellus, eget scelerisque augue ipsum dapibus ex. Nulla facilisi. Aliquam urna lorem, imperdiet eget est in, accumsan lacinia quam.


Lorem ipsum dolor sit amet
quote-icon
Donec maximus dapibus
Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec maximus dapibus semper. 

Author Name


Lorem ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec maximus dapibus semper. Sed ipsum ex, aliquam non lacinia et, porta ut turpis. In id tortor a nisl eleifend pellentesque quis id lacus. Nam dapibus augue diam, nec feugiat mauris malesuada nec.

Quisque nec tempus metus, sit amet porttitor quam. Nam nibh enim, ultricies vitae molestie in, vulputate viverra purus. Cras eget efficitur urna. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Donec eu erat dolor. Nulla feugiat, massa sed mollis pulvinar, nibh dolor gravida tellus, eget scelerisque augue ipsum dapibus ex. Nulla facilisi. Aliquam urna lorem, imperdiet eget est in, accumsan lacinia quam.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

true

About 19 to Zero

19 to Zero is a not-for-profit coalition of academics, public health experts, behavioural economists, and creative professionals working to understand, engage with, and ultimately shift public perceptions towards healthier behaviours. 19 to Zero originally launched with a focus on encouraging safer public health behaviours during the COVID-19 pandemic. Since then, 19 to Zero has continued to build vaccine confidence and help close care gaps across a range of health and disease domains.

true

Contact

Ozgur Uzun

365-440-1930
Email

true
true